Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Aga LLC

Neither a doctor nor a teaching hospital

Research payments

$2,421,501

950 payments

Through program year 2025, Aga LLC is reported as receiving $2,421,501 in research payments, across 950 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $312,786 65
2024 Research $468,303 588
2023 Research $201,563 56
2022 Research $498,865 92
2021 Research $299,989 115
2020 Research $64,080 15
2019 Research $575,916 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Celgene Corporation $541,663 8 payments
  2. Janssen Research & Development, LLC $504,977 38 payments
  3. AbbVie, Inc. $370,166 52 payments
  4. Pfizer Inc. $291,727 87 payments
  5. Arena Pharmaceuticals, Inc. $279,793 54 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $195,011 600 payments
  7. Genentech, Inc. $96,546 49 payments
  8. Roche Products Limited $92,916 28 payments
  9. Bausch Health US, LLC $46,831 33 payments
  10. F. Hoffmann-La Roche AG $1,871 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Doubleblind Parallelgroup Study to Assess the Efficacy and Safety of Oral Etrasimod As Induction and Maintenance Therapy for Moderately to Severely Active Crohns Disease $465,184 89 payments
  2. A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease $326,241 19 payments
  3. PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) $231,342 1 payment
  4. A Phase 3B Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease $189,385 596 payments
  5. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $187,494 22 payments
  6. A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis $143,465 15 payments
  7. PhII Stepstone RPC1063 Induction in Moderately to Severely CD as Induction with LT(RPC01-2201) (BMS Study Number: IM047-P13) (RPC01-2201) $109,719 1 payment
  8. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) $91,642 2 payments
  9. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $83,645 21 payments
  10. An Openlabel Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $77,289 34 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record